Tumor cavitation: Impact on objective Response Evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 404-410

  Crabb, Simon J ^a   Patsios, Demetris ^a   Sauerbrei, Eric ^a   Ellis, Peter M ^a   Arnold, Andrew ^a   Goss, Glenwood ^a   Leighl, Natasha B ^a   Shepherd, Frances A ^a   Powers, Jean ^a   Seymour, Lesley ^a   Laurie, Scott A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CEDIRANIB; CISPLATIN; GEMCITABINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; REBIMASTAT; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG CAVITATION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PACLITAXEL; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58549092392     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2545     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Gridelli C, Gallo C, Shepherd FA, et al: Gem-citabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025-3034, 2003
3. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
4. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
5. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
6. Dudek AZ, Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Cancer Invest 23:193-200, 2005
7. Laack E, Scheffler A, Burkholder I, et al: Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50:51-58, 2005
8. Nishi M, Abe Y, Tomii Y, et al: Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol 26: 1517-1524, 2005
9. Seto T, Higashiyama M, Funai H, et al: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53:91-96, 2006
10. Shimanuki Y, Takahashi K, Cui R, et al: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 183:29-42, 2005
11. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
12. Manegold C, von Pawel J, Zatloukal P, et al: Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25:388s, 2007 (suppl; abstr LBA7514)
13. Hanrahan EO, Heymach JV: Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13:S4617-S4622, 2007
14. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007
15. Goss GD, Laurie S, Shepherd F, et al: IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cis-platin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC) - A study of the NCIC Clinical Trials Group. J Clin Oncol 25:421s, 2007 (suppl;abstr 7649)
16. Laurie SA, Gauthier I, Arnold A, et al: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26:1871-1878, 2008
17. Ryan CJ, Stadler WM, Roth B, et al: Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25:445-451, 2007
18. Smith NR, James NH, Oakley I, et al: Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6:2198-2208, 2007
19. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Leighl NB, Paz-Ares L, Douillard JY, et al: Randomized phase III study of matrix metallopro-teinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J Clin Oncol 23:2831-2839, 2005
22. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevaci-zumab plus carboplatin and paclitaxel with carbopla-tin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
23. Marom EM, Martinez CH, Truong MT, et al: Tumor cavitation during therapy with antiangiogen-esis agents in patients with lung cancer. J Thorac Oncol 3:351-357, 2008
24. Sandler AB, Johnson DH, Brahmer J, et al: Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24:381s, 2006 (suppl; abstr 7068)
25. Marten K, Engelke C: Computer-aided detection and automated CT volumetry of pulmonary nodules. Eur Radiol 17:888-901, 2007
26. Benjamin RS, Choi H, Macapinlac HA, et al: We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764, 2007
27. Ceresoli GL, Chiti A, Zucali PA, et al: Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev 33:533-541, 2007
28. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007
29. Schwartz LH, Colville JAC, Ginsberg MS, et al: Measuring tumor response and shape change on CT: Esophageal cancer as a paradigm. Ann Oncol 17:1018-1023, 2006
30. Eisenhauer EA: Response evaluation: Beyond RECIST. Ann Oncol 18:ix29-ix32, 2007